

Irvine, CA, October, 2010, MiCardia Corporation announced their participation in a scientific session at the 25th Annual EACTS (European Association of Cardio-Thoracic Surgeons) meeting in Geneva on September 14, 2010.

The EACTS session was the first special topic session on adjustable annuloplasty rings. The session, titled “Adjustable Rings, a Better Tool for Repair” was designed to introduce the surgical community to new technologies in mitral valve repair. The session was moderated by Dr. Michael Mack, from Dallas, Texas and included presentations by Dr. Hugo Vanerman, Aalst, Belgium, Dr. Volkmar Falk, Zurich, Switzerland and Dr. Francesco Maisano, Milan, Italy.

Dr. Markus Czesla of Sana Herzchirurgie, Stuttgart, Germany presented clinical data from MiCardia’s DYANA trial. The trial was completed in 2009 and included 35 patients implanted with an intra-operatively, dynamically adjustable device, the Company’s **enCor™** device. **enCor** allows surgeons to address any residual mitral regurgitation real-time, off-pump, on a beating heart, thereby, avoiding longer pump times and any additional procedures that might be necessary to maximize clinical outcomes.

Dr. Czesla commented, “This intelligent technology offers surgeons a new level of quality with excellent long-term results and opens up unique options in the further treatment of patients who require mitral valve repair.”

MiCardia’s **enCor** Mitral Valve Repair System™ received CE Mark approval on October 27, 2010. The company has a unique, second generation product, designed with the option to adjust days, months or years after the initial procedure. A clinical trial on the **enCor** sq is planned for early 2011. In addition, the company’s third generation device, the **enCor**tc, is a trans-catheter product, designed to be implanted interventionally.